We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Rocket Pharmaceuticals Inc
15 own
9 watching
Current Price
$22.23
$-0.16
(-0.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,508.06M
52-Week High
23.48
52-Week Low
7.565
Average Volume
0.61M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,508.06M52-Week High23.4852-Week Low7.565Average Volume0.61MDividend Yield--P/E Ratio--What does the Rocket Pharmaceuticals Inc do?
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The product pipeline includes Trabodenoson, a monotherapy dosed in an eye drop that is in Phase III clinical trials; Trabodenoson-Latanoprost Fixed-Dose Combination, which has completed Phase II study for use in patients with higher intraocular pressures; and Trabodenoson for optic neuropathy and degenerative retinal diseases. The company was founded in 1999 and is headquartered in Lexington, Massachusetts.
Read More
How much money does Rocket Pharmaceuticals Inc make?
News & Events about Rocket Pharmaceuticals Inc.
Ticker Report
23days ago
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Rating) have received a consensus rating of Moderate Buy from the thirteen brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation ...
Business Wire
1month ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and...
Business Wire
1month ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces positive clinical data from its lentiviral (LV)-based gene therapy...
Zolmax
1month ago
Rocket Pharmaceuticals (NASDAQ:RCKT Get Rating) had its price target lowered by SVB Leerink from $56.00 to $54.00 in a report issued on Tuesday, MarketBeat.com reports. SVB Leerink currently has an outperform rating on the biotechnology companys stock. SVB Leerink also issued estimates for Rocket ...
Business Wire
2 months ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a...
Frequently Asked Questions
Frequently Asked Questions
What is Rocket Pharmaceuticals Inc share price today?
Can Indians buy Rocket Pharmaceuticals Inc shares?
How can I buy Rocket Pharmaceuticals Inc shares from India?
Can Fractional shares of Rocket Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Rocket Pharmaceuticals Inc stocks?
What is today’s traded volume of Rocket Pharmaceuticals Inc?
What is today’s market capitalisation of Rocket Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Rocket Pharmaceuticals Inc?
What percentage is Rocket Pharmaceuticals Inc down from its 52-Week High?
What percentage is Rocket Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$22.23
$-0.16
(-0.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.